undisclosed next-generation TCR-T cell therapy / ImmunoScape - LARVOL DELTA

ImmunoScape Pte. Ltd…and EDBI that is developing next-generation TCR-based cancer immunotherapies, today announced the presentation of compelling new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026. (PharmiWeb) - "Robust in vivo expansion and anti-tumor effect: In an animal model, Seed and Boost combination therapy drove significant TCR-T cell expansion and anti-tumor effect at both standard and low cell doses; 100% survival in a high tumor burden ovarian cancer model: In an animal model, the Seed and Boost combination achieved 100% survival, compared to significant mortality in the monotherapy arms. Pancreatic tumor infiltration: In an animal model, the Seed and Boost combination resulted in significant infiltration of tumor-specific T cells into pancreatic tumors."

Preclinical • Solid Tumor